Elise C. Kohn

Research interests

Publications

• Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30180-7

• PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline

  Journal of Clinical Oncology · 2020 · 10.1200/jco.20.01924

• Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline

  Journal of Clinical Oncology · 2020 · 10.1200/jco.19.02960

• Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30009-3

• Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2016.72.1340

• Ovarian cancer

  The Lancet · 2014 · https://doi.org/10.1016/s0140-6736(13)62146-7

• Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70391-2

• The MAPK pathway across different malignancies: A new perspective

  Cancer · 2014 · https://doi.org/10.1002/cncr.28864

• PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

  Annals of Oncology · 2013 · 10.1093/annonc/mdt384

• Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis

  International Journal of Cancer · 2011 · 10.1002/ijc.26217

• Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a src-dependent fashion

  Angiogenesis · 2011 · https://doi.org/10.1007/s10456-011-9241-1

• Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.10.8332

• High-resolution serum proteomic features for ovarian cancer detection.

  Endocrine Related Cancer · 2004 · https://doi.org/10.1677/erc.0.0110163

• What's in the ‘BAG’? – a functional domain analysis of the BAG-family proteins

  Cancer Letters · 2002 · https://doi.org/10.1016/s0304-3835(02)00456-1

• Use of proteomic patterns in serum to identify ovarian cancer

  The Lancet · 2002 · https://doi.org/10.1016/s0140-6736(02)07746-2

• Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer

  PROTEOMICS · 2002 · https://doi.org/10.1002/1615-9861(200201)2:1<76::aid-prot76>3.0.co;2-o

• Angiogenesis and Metastasis

  Ovarian cancer · 2002 · https://doi.org/10.1007/978-1-4757-3587-1_17

• Clinical proteomics: translating benchside promise into bedside reality

  Nature Reviews Drug Discovery · 2002 · 10.1038/nrd891

• Clinical Proteomics

  JAMA · 2001 · https://doi.org/10.1001/jama.286.18.2211

• The microenvironment of the tumour–host interface

  Nature · 2001 · https://doi.org/10.1038/35077241

• Tumor angiogenesis in advanced stage ovarian carcinoma.

  PubMed · 1995

• Angiogenesis: role of calcium-mediated signal transduction.

  Proceedings of the National Academy of Sciences · 1995 · https://doi.org/10.1073/pnas.92.5.1307

• Molecular insights into cancer invasion: strategies for prevention and intervention.

  PubMed · 1995

• Dose-Intense Taxol: High Response Rate in Patients With Platinum-Resistant Recurrent Ovarian Cancer

  JNCI Journal of the National Cancer Institute · 1994 · 10.1093/jnci/86.1.18

• Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors.

  PubMed · 1990

Current projects

No projects listed.